News | April 11, 2025
US court lifts launch restrictions on Sun Pharma's autoimmune drug
Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI
Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI
AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
DOVBLERON marks the 13th addition to Innovent’s commercial portfolio
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Subscribe To Our Newsletter & Stay Updated
